News

The director of research at St. Luke’s Sleep Medicine and Research Center discussed the motivation behind her study assessing solriamfetol in patient’s adherent and nonadherent to primary OSA therapy.

NMOSD is associated with elevated levels of the pleiotropic cytokine interleukin-6, making the cytokine an apt therapeutic target.

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed topline results from the EMPhASIS trial of IMU-838.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

Just weeks after receiving an EU marketing authorization, the FDA has issued a complete response letter to Biogen for its sBLA related to the subcutaneous administration of natalizumab (Tysabri).

A trio of clinicians from Georgetown University explore the current status of disease-modifying therapies for individuals with Parkinson disease.

Apic Bio plans to initiate a phase 1/2 clinical trial in late 2021 or early 2022 as a multi-center, 3-part study to evaluate APB-102 in patients with SOD1-ALS mutations.

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.

Investigators also studied how use of a patient engagement tool influenced adherence rates to PAP.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, outlined the different tests that make up the MSPT battery.

Surgical care for PD is safe and effective, and should no longer be treated as a consideration of last resort, but as a treatment option discussed early in the disease course with the patient and their family.

Researchers compared sleep measures between the Fitbit Charge 3, the Actigraph GT9X accelerometer, and polysomnography.

Formerly known as BIIB067, the antisense oligonucleotide is expected to be available for rapidly progressing patients in mid-July 2021, and for the broader SOD1-ALS population in the fall.

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

The importance of being prepared for the unexpected, including having a seizure action plan and having access to rescue medication, is paramount to ensuring continuity of care for patients with epilepsy.

The director of the MedStar Georgetown Headache Center spoke to the considerations she makes in determining when patients with migraine may need a nonoral therapy to address their disease.

The assistant professor of neurology at the Weill Cornell Brain and Spine Center discussed his presentation at AAN 2021 evaluating racial disparities in smoking cessation among stroke survivors.

The Neurolutions IpsiHand Upper Extremity Rehabilitation system is indicated for use in patients with chronic stroke age 18 or older undergoing stroke rehabilitation to facilitate muscle re-education.

Researchers also found that EDSS score pre-pregnancy was associated with the likelihood of post-partum relapse for patients with multiple sclerosis.

The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about new opportunities for research into brain lesions and microglia.

Changes in mean use of airway therapy from baseline to week 40 of the open-label extension were minimal for those on solriamfetol.

The director of the MedStar Georgetown Headache Center spoke to the efficacy and application of a new formulation of the longstanding agent dihydroergotamine in the treatment of migraine.

Advances in MRI and MRS techniques and protocols enhance diagnosis of neuromuscular disorders and provide prognostic and intervention efficacy biomarkers.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed findings from his study on PAP adherence.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of MS that need more research, as well as other factors impacting care, such as comorbidities.

In addition to a number of positive attributes stemming from telehealth use, most providers claimed they were interested in digitally prescribing headache apps and remotely monitoring patient symptoms.

Guest Editor-in-Chief Jill Giordano Farmer, DO, MPH, shared her perspective on the importance of April as the annual Parkinson disease awareness month.

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed how the cognitive mobile toolbox can be used to assess cognition in all populations.

Here's what is coming soon to NeurologyLive.

Three patients included in the study showed positive trends across both I-RODS and Jamar grip strength following treatment with lenalidomide.